Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Stefanik

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 20, 2004
Does dose matter?Yi Zhang, Mae Thamer, Kevin Stefanik, et al.
Seminars in Dialysis|May 18, 2004
Improved survival with higher hematocrits: where is the evidence?Dennis J Cotter, Kevin Stefanik, Yi Zhang, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 27, 2006
Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United StatesMae Thamer, Yi Zhang, James Kaufman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 20, 2004
Epoetin requirements predict mortality in hemodialysis patientsYi Zhang, Mae Thamer, Kevin Stefanik, et al.
Journal of Clinical Epidemiology|November 6, 2004
Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patientsDennis J Cotter, Kevin Stefanik, Yi Zhang, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 20, 2004
Does dose matter?Yi Zhang, Mae Thamer, Kevin Stefanik, et al.
Seminars in Dialysis|May 18, 2004
Improved survival with higher hematocrits: where is the evidence?Dennis J Cotter, Kevin Stefanik, Yi Zhang, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 27, 2006
Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United StatesMae Thamer, Yi Zhang, James Kaufman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 20, 2004
Epoetin requirements predict mortality in hemodialysis patientsYi Zhang, Mae Thamer, Kevin Stefanik, et al.
Journal of Clinical Epidemiology|November 6, 2004
Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patientsDennis J Cotter, Kevin Stefanik, Yi Zhang, et al.
Pageof 1